---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-033948"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:26:50.642665+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Monopar presents Phase 2 data showing ALXN1840 rapidly improves copper balance in Wilson disease

## Summary
- Oral presentation at AASLD 2025: 'Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline.'
- Mean daily copper balance significantly improved vs. pre-treatment baseline in 8 patients on ALXN1840.
- Improvement observed during 15 mg once-daily (days 1-28) and entire treatment period (days 1-39).
- Copper balance improved primarily via increased fecal copper excretion; data available on Monopar's website.

## SEC filing metadata
- accession: 0001437749-25-033948
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774925033948/0001437749-25-033948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774925033948/mnpr20251108_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-033948
- JSON: https://secwatch.observer/filing/0001437749-25-033948.json
- Plain text: https://secwatch.observer/filing/0001437749-25-033948.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.